Comparative Pharmacology
Head-to-head clinical analysis: LEVORPHANOL TARTRATE versus NORCET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVORPHANOL TARTRATE versus NORCET.
LEVORPHANOL TARTRATE vs NORCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levorphanol is a potent opioid analgesic that acts as a mu-opioid receptor agonist. It also has NMDA receptor antagonist activity, inhibits norepinephrine and serotonin reuptake, and acts as a sigma receptor agonist, contributing to its analgesic effects and reduced tolerance development.
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
2 mg orally every 6-8 hours as needed for pain; for opioid-tolerant patients, doses up to 4 mg orally every 6-8 hours may be used. Parenterally: 1-2 mg subcutaneously or intramuscularly every 6-8 hours; may be given intravenously at 0.5-1 mg every 6-8 hours.
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
None Documented
None Documented
11-16 hours; extended in hepatic impairment (up to 30 hours).
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly
Renal: approximately 30% as unchanged drug and 50% as glucuronide conjugates; fecal: 20% via biliary excretion.
Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic